MedTrace Logo

DEFENDOR: A Multicenter Prospective Observational Post-registration stuDy of Extimia® (INN: empEgfilrastim) to Evaluate Efficacy and saFEty in patieNts With soliD tumORs

NCT04811443 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2021-03-23

No results posted yet for this study

Summary

This study was designed to evaluate the efficacy and safety of Extimia® (INN - empegfilgrastim) in reducing the frequency, duration of neutropenia, the incidence of febrile neutropenia and infections caused by febrile neutropenia in patients with solid tumours receiving myelosuppressive therapy

Conditions

  • Patients With Solid Tumours Who Receive Myelosupressive Therapy

Interventions

DRUG

Empegfilgrastim

Extimia®

Sponsors & Collaborators

  • Biocad

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-12
Primary Completion
2022-06-12
Completion
2022-06-12

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04811443 on ClinicalTrials.gov